Your browser doesn't support javascript.
loading
Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-T Trial.
Khan, Atif J; Chen, Peter Y; Yashar, Catheryn; Poppe, Matthew M; Li, Linna; Abou Yehia, Zeinab; Vicini, Frank A; Moore, Dirk; Dale, Roger; Arthur, Doug; Shah, Chirag; Haffty, Bruce G; Kuske, Robert.
Afiliación
  • Khan AJ; Memorial Sloan Kettering Cancer Center, New York, New York; Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, Michigan. Electronic address: khana7@mskcc.org.
  • Chen PY; Beaumont Health System, Royal Oak, Michigan.
  • Yashar C; University of California San Diego/Moores Cancer Center, La Jolla, California.
  • Poppe MM; Huntsman Cancer Institute, Salt Lake City, Utah.
  • Li L; Bryn Mawr Hospital, Bryn Mawr, Pennsylvania.
  • Abou Yehia Z; Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, Michigan.
  • Vicini FA; Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, Michigan.
  • Moore D; Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, Michigan.
  • Dale R; Imperial College, London, United Kingdom.
  • Arthur D; Virginia Commonwealth University, Massey Cancer Center, Richmond, Virginia.
  • Shah C; Cleveland Clinic Cancer Center, Cleveland, Ohio.
  • Haffty BG; Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, Michigan.
  • Kuske R; Arizona Breast Cancer Specialists, Scottsdale, Arizona.
Int J Radiat Oncol Biol Phys ; 104(1): 67-74, 2019 05 01.
Article en En | MEDLINE | ID: mdl-30611839
PURPOSE: Shorter courses of accelerated partial-breast irradiation delivered as single-fraction intraoperative therapy are now offered as an alternative to 4 to 6 weeks of whole-breast irradiation after lumpectomy. However, this approach has potential shortcomings in patient selection and target volume definition and in dosimetric, radiobiological, and logistical issues. We designed a prospective, phase 2, multi-institution clinical trial to study 2- or 3-day accelerated partial breast irradiation delivered with brachytherapy applicators. METHODS AND MATERIALS: This trial treats select breast cancers after breast-conserving surgery with brachytherapy applicators that deliver 22.5 Gy in 3 fractions of 7.5 Gy. The planning treatment volume was 1 to 1.5 cm beyond the surgical cavity. Eligible women were aged ≥45 years with unicentric invasive or in situ tumors ≤3.0 cm with positive estrogen or progesterone receptors and no metastasis to axillary nodes that have been excised with negative margins. Strict dosimetric parameters were required to be met before acceptance into the trial. RESULTS: A group of 200 patients was prospectively enrolled and followed for a minimum of 6 months. Two- or 3-day brachytherapy was associated with low acute or subacute toxicity, 97.25% excellent or good cosmetic outcomes, and excellent local control in select breast cancers. CONCLUSIONS: Ultrashort breast brachytherapy is dosimetrically feasible and can be delivered with excellent short-term tolerance and low toxicity.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Braquiterapia / Neoplasias de la Mama Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Braquiterapia / Neoplasias de la Mama Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos